Evidence map›Paper›PMID 36843571›Full record

ArticleDrug delivery2023

Preparation and

Yan Li, Hong Yin, Chensi Wu, Jia He, Chunyan Wang, Bo Ren, Heping Wang, Dandan Geng, Yirong Zhang, Ligang Zhao

Abstract read
In one paragraph

Article in Drug delivery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Aprepitant: Review on Solubility Enhancement.Recent advances in drug delivery and formulation · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yan LiDepartment of Pharmacy, Tangshan Maternal and Child Health Hospital, Tangshan, China.
Hong YinSchool of Pharmacy, North China University of Science and Technology, Tangshan, China.
Chensi WuSchool of Pharmacy, North China University of Science and Technology, Tangshan, China.
Jia HeDepartment of Pharmacy, Hohhot Hospital of Traditional Chinese Medicine and Mongolian Medicine, Hohhot, China.
Chunyan WangDepartment of Pharmacy, Tangshan Maternal and Child Health Hospital, Tangshan, China.
Bo RenSchool of Pharmacy, North China University of Science and Technology, Tangshan, China.
Heping WangSchool of Pharmacy, North China University of Science and Technology, Tangshan, China.
Dandan GengSchool of Pharmacy, North China University of Science and Technology, Tangshan, China.
Yirong ZhangSchool of Pharmacy, North China University of Science and Technology, Tangshan, China.
Ligang ZhaoSchool of Pharmacy, North China University of Science and Technology, Tangshan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In present, there was no detailed report on the formulation optimization and quality evaluation of aprepitant (APT) injectable lipid emulsion (APT-IE). The aim of the present investigation was to prepare and evaluate its properties of APT-IE loaded with an APT phospholipid complex (APT-PC)

Indexed as

PhospholipidsAdministration, IntravenousAprepitantBiological AvailabilityEmulsionsParticle SizeAprepitantEmulsionsPhospholipidsAprepitantlipid injectable emulsionpharmacokineticsresponse surface methodologytissue distribution

Identifiers

PMID36843571
PMCPMC9979997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.